Clinical Trial

A Study of LY3985863 in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-12; most recent amendment 2026-03-10.
Status change: Active, Not Recruiting → Completed 2026-03-10
Status change: Recruiting → Active, Not Recruiting 2025-11-19
Status change: Not Yet Recruiting → Recruiting 2025-09-03
Trial Details
NCT Number NCT07030127
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 24 participants
Start Date 2025-08-11
Primary Completion 2026-02-24 (estimated)
Study Completion 2026-02-24 (estimated)
Updated on ClinicalTrials.gov 2026-03-11